AnalystsInsight

Ed Arce (Westpark Capital): Analyst Track Record and Price‑Target Accuracy

Ed Arce is one of the top‑ranked analysts in Exent’s 7‑year backtest. What Ed covers, how Ed’s ratings lean, how fast price targets were reached and the ratings from before the last 30 days; the full record and the newest calls are members‑only.

Published Updated 2 min readHow we research

Key takeaways

  • Ed Arce ranks among the top 50 healthcare analysts in Exent’s ranking, scored on a 7‑year backtest.
  • The exact rank, price‑target hit rate and live calls are members‑only in Exent Gems.
  • Most‑covered stocks: ARCT, MIRM, UNCY, AKBA.
  • In the past year Ed’s ratings were 100% Buy, 0% Hold and 0% Sell.

Ed Arce’s track record at a glance

Ed Arce of Westpark Capital ranks among the top 50 healthcare analysts in Exent’s ranking, with a focus on healthcare. The top of the ranking is what Exent Gems follows, so Ed’s exact rank, hit rate and live calls are for members.

MetricEd ArceAll analysts
Exent rank—
Price‑target hit rate52.4%
Calls up after 12 months64.0%
Median 12‑month return of calls+13.4%
Median days to hit target91 days
Stocks covered34—

How fast price targets were reached

Time to reach the targetEd Arce
Under 30 days19.6%
30–90 days22.7%
90–180 days22.7%
Over 180 days35.1%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Ed Arce covers most

ARCT · MIRM · UNCY · AKBA · PLRX · SGMT · ASMB · ARDX

In the past year Ed’s ratings were 100% Buy, 0% Hold and 0% Sell.

Ed Arce’s latest ratings

DateStockActionRatingPrice target
Sep 8, 2026AKBAInitiated Coverage: BuyBuy$4.50
Apr 30, 2026TLPHInitiated CoverageBuy$3.00
Apr 30, 2026TLPHInitiated Coverage: BuyBuy$3.00
Sep 17, 2025MTVAMaintainedBuy$132.00
Sep 17, 2025MTVAMaintained: BuyBuy$132.00
Sep 17, 2025MTVAReiterated: BuyBuy$132.00
Sep 4, 2025MTVAInitiated Coverage: BuyBuy$132.00
Sep 4, 2025MTVAInitiated CoverageBuy$132.00
Apr 16, 2025MTVAMaintainedBuy$132.00
Apr 16, 2025MTVAMaintained: BuyBuy$132.00
Apr 16, 2025MTVAReiterated: BuyBuy$132.00
Apr 11, 2025ARCTMaintained: BuyBuy$60.00
  • Sep 8, 2026
    Stock
    AKBA
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $4.50
  • Apr 30, 2026
    Stock
    TLPH
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $3.00
  • Apr 30, 2026
    Stock
    TLPH
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $3.00
  • Sep 17, 2025
    Stock
    MTVA
    Action
    Maintained
    Rating
    Buy
    Price target
    $132.00
  • Sep 17, 2025
    Stock
    MTVA
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $132.00
  • Sep 17, 2025
    Stock
    MTVA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $132.00
  • Sep 4, 2025
    Stock
    MTVA
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $132.00
  • Sep 4, 2025
    Stock
    MTVA
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $132.00
  • Apr 16, 2025
    Stock
    MTVA
    Action
    Maintained
    Rating
    Buy
    Price target
    $132.00
  • Apr 16, 2025
    Stock
    MTVA
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $132.00
  • Apr 16, 2025
    Stock
    MTVA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $132.00
  • Apr 11, 2025
    Stock
    ARCT
    Action
    Maintained: Buy
    Rating
    Buy
    Price target
    $60.00

Ratings from the last 30 days are members‑only in Exent Gems, with the stocks where several top‑ranked analysts agree; older ratings are shown in full.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Ed Arce’s full record and latest ratings, without the 30‑day delay.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring, Ed Arce ranks among the top 50 healthcare analysts in Exent’s ranking, based on a 7-year backtest of price-target hit rate, returns after calls and number of ratings. The exact rank, hit rate and live calls are members-only in Exent Gems (exent.ai/radar). Past accuracy does not guarantee future accuracy.

Ed Arce’s price-target hit rate is part of the members-only record in Exent Gems (exent.ai/radar). For comparison, the average analyst’s price targets were reached 52.4% of the time.

Ed Arce (Westpark Capital) covers 34 stocks, mostly in healthcare. The most frequently rated are ARCT, MIRM, UNCY, AKBA, PLRX.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.